LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1
IC-ORR by BICR2
Lorlatinib demonstrated 82% IC-ORR in patients with measurable brain metastases at baseline
Example
IC Time to Progression by BICR2,3
Adapted from Shaw AT, et al. 2020.
*OR >1 indicates better outcome for lorlatinib relative to crizotinib.
†LORBRIQUA®, n=17; crizotinib, n=13 with measurable CNS lesions at baseline as assessed by the BICR.
ALK+, anaplastic lymphoma kinase-positive; BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; DoR, duration of response; ESMO, European Society for Medical Oncology; HR, hazard ratio; IC, intracranial; IC-ORR, intracranial objective response rate; NE, not evaluable; NR, not reached; NSCLC, non-small cell lung cancer; OR, odds ratio; PR, partial response.
References:
Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-LOR-IND-0129 June 2022
Example
The American Cancer Society funds and conducts research, shares expert information and provides support for patients who have been affected by cancer.
The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022